To study the concept of seven Dravya in cause and subsequent development of Eka Kushtha and its principle management with special reference to blood letting with Jalauka
Phase 3
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2022/06/043034
- Lead Sponsor
- Rajiv Gandhi Ayurvedic college and Hospital Paprola district kangra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Patients showing sign and symptoms of Eka Kushtha (psoriasis).
2) Age group 16-70 years should be included in the trial.
3) Patients willing for trial will be included in the study after obtaining detailed in formed consent.
Exclusion Criteria
a. Patients suffering from Anemia, Haemophillia A, Haemophillia B, Septic disorders, Allergic reaction to (Hirudin) active ingredient in leech saliva, Immunocompromised, Hypertension, Diabetes-mellitus,
Hepatitis B.
b. Patients below 16 year and above 70 year of age.
C. Patients not willing for trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Area of Involvement- The body is divided into four sections - Head (10% of a persons skin), arms (20%), trunk (30%) and legs (40%). Each of these area is scored and then four scores are combined into final PASI. <br/ ><br> <br/ ><br>2. Within each area the severity is estimated by three clinical signs: Erythema, Induration, Desquamation.Timepoint: 2 month
- Secondary Outcome Measures
Name Time Method Cured: 100% relief in signs and symptoms. Marked improvement: More than 75% improvement in signs and symptoms will be recorded as marked improvement. <br/ ><br>Moderate improvement: 51% to 75% improvement in signs and symptoms will be considered as moderate improvement. <br/ ><br>Mild improvement: 25% to 50% improvement in sign and symptoms will be considered as mild improvement. No improvement: Less than 25% reduction in signs and symptoms will be noted as unchanged.Timepoint: 3month